Miransertib
Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research[1]. Miransertib is effective against Leishmania[2].
Product Specifications
CAS Number
1313881-70-7
Product Name Alternative
ARQ-092
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Akt; Parasite
Type
Reference compound
Related Pathways
Anti-infection; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/ARQ-092.html
Concentration
10mM
Purity
99.32
Solubility
DMSO : 12.5 mg/mL (ultrasonic)
Smiles
NC1=NC=CC=C1C2=NC3=CC=C(C4=CC=CC=C4)N=C3N2C5=CC=C(C6(N)CCC6)C=C5
Molecular Formula
C27H24N6
Molecular Weight
432.52
Precautions
H315, H319, H320
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Akt1; Akt2; Akt3; Leishmania
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Active Recombinant Human JMJD5 protein, His-tagged
Recombinant Buchnera aphidicola subsp. Acyrthosiphon pisum Prolipoprotein diacylglyceryl transferase (lgt), partial
